In a 38-year-old patient with a ventricular septal defect and an unspecified cardiac murmur who now has progressive erythrocytosis (elevated red blood cell count, hemoglobin, and hematocrit), an LDL cholesterol of 145 mg/dL, and an HbA1c of 5.8 % (prediabetes), what is the appropriate next step in management?

Urgent Hematology Referral for Progressive Erythrocytosis with Cardiac Evaluation

The most critical next step is immediate referral to hematology for comprehensive evaluation of the progressive erythrocytosis, as this patient with a ventricular septal defect (VSD) may be developing Eisenmenger syndrome or secondary polycythemia requiring specialized management. 1, 2

Primary Concern: Progressive Erythrocytosis in VSD Patient

Why This Demands Urgent Attention

In a 38-year-old with VSD and progressively increasing red blood cell indices, you must distinguish between:

• Secondary erythrocytosis from right-to-left shunting (Eisenmenger syndrome developing)
• Primary polycythemia vera (JAK2-driven myeloproliferative neoplasm)
• Other causes of secondary erythrocytosis

The progressive nature is the red flag here. 1, 2, 3

Critical Diagnostic Pathway for Erythrocytosis

Step 1: Immediate hematology workup should include:

• JAK2 mutation testing (V617F and exon 12) to exclude polycythemia vera 2
• Serum erythropoietin level (elevated/normal suggests secondary; low suggests PV) 2
• Oxygen saturation measurement at rest and with exertion
• Complete blood count with peripheral smear

Step 2: Cardiac hemodynamic assessment:

• Echocardiography with bubble study to assess shunt direction and magnitude (Qp:Qs ratio) 4
• Pulmonary artery pressure estimation 4
• Right ventricular size and function
• Assessment for Eisenmenger physiology (shunt reversal)

The Eisenmenger Concern

Critical pitfall: If this patient has developed Eisenmenger syndrome (right-to-left shunting with pulmonary vascular disease), the erythrocytosis is a compensatory mechanism to improve oxygen-carrying capacity. 1 In this scenario:

• Phlebotomy is potentially harmful and should only be done for hyperviscosity symptoms (headache, visual changes, paresthesias) 1
• Target hematocrit should remain >65% unless symptomatic 1
• VSD closure would be contraindicated if severe pulmonary hypertension exists (PA pressure >2/3 systemic, PVR >2/3 systemic, or net right-to-left shunt) 4

VSD-Specific Management Considerations

Based on the 2019 ACC/AHA guidelines 4:

VSD closure is indicated if:

• Left ventricular volume overload present
• Qp:Qs ≥1.5:1
• PA systolic pressure <50% systemic
• PVR <1/3 systemic

VSD closure is HARMFUL if:

• Severe PAH with PA pressure >2/3 systemic
• PVR >2/3 systemic
• Net right-to-left shunt (Eisenmenger)

Secondary Issues: Metabolic Risk Factors

Prediabetes Management (HbA1c 5.8%)

Initiate intensive lifestyle modification immediately 5, 6:

• Target 7% body weight reduction if overweight
• 150 minutes/week moderate-intensity aerobic activity 7
• Dietary modification: <7% calories from saturated fat, increased fiber intake 5
• Repeat HbA1c in 3 months

Do NOT start metformin yet - HbA1c 5.8% warrants aggressive lifestyle intervention first. Consider pharmacotherapy only if HbA1c progresses to ≥6.5% or remains ≥6.0% after 3-6 months of lifestyle changes. 5, 6

LDL Cholesterol 145 mg/dL

Start therapeutic lifestyle changes now 7:

• <7% calories from saturated fat
• <200 mg/day dietary cholesterol
• Plant stanols/sterols (2 g/day)
• Soluble fiber (10-25 g/day)
• Weight reduction and increased physical activity

Statin therapy threshold: Given this patient's cardiac disease (VSD), consider them at elevated cardiovascular risk. After 12 weeks of lifestyle modification, if LDL remains ≥130 mg/dL, initiate statin therapy with goal LDL <100 mg/dL. 7, 8, 5

Specific Action Plan

Within 1 Week:

1. Hematology referral - JAK2 testing, EPO level, oxygen saturation assessment
2. Cardiology referral (if not already established) - echocardiography with shunt assessment
3. Initiate lifestyle modifications for prediabetes and dyslipidemia

Within 1 Month:

1. Complete erythrocytosis workup
2. Hemodynamic assessment of VSD (echo ± cardiac catheterization if indicated)
3. Reassess lipids after lifestyle changes initiated

Within 3 Months:

1. Repeat HbA1c
2. Repeat lipid panel
3. Consider statin initiation if LDL goal not met
4. Definitive management plan for erythrocytosis based on etiology

Critical Warnings

Do NOT:

• Start empiric phlebotomy without determining etiology of erythrocytosis 1
• Recommend VSD closure without hemodynamic assessment 4
• Delay hematology evaluation given progressive nature of blood count changes
• Start diabetes medications at HbA1c 5.8% without lifestyle intervention trial first

The progressive erythrocytosis is the most concerning finding requiring immediate subspecialty evaluation, as it may indicate evolving Eisenmenger physiology or primary hematologic disease, both of which fundamentally alter management.